Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Jan 06, 2026
Brokers Issue Forecasts for scPharmaceuticals Inc.s FY2021 Earnings (NASDAQ:SCPH)
06:32am, Sunday, 14'th Nov 2021 Dakota Financial News
scPharmaceuticals Inc. (NASDAQ:SCPH) SVB Leerink raised their FY2021 EPS estimates for scPharmaceuticals in a report released on Tuesday, November 9th. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings of ($1.05) per share for the year, up from their previous forecast of ($1.23). SVB Leerink currently has a Market Perform []
scPharmaceuticals to Present at the Jefferies London Healthcare Conference
08:30am, Tuesday, 02'nd Nov 2021
BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
07:00am, Wednesday, 11'th Aug 2021
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on trac
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
04:08pm, Tuesday, 13'th Jul 2021
Reduced average 30-day heart failure related costs by $17,753 (p
SCPH Stock Price Increases Over 18%: Why It Happened
12:50pm, Thursday, 01'st Jul 2021
The stock price of scPharmaceuticals Inc (NASDAQ: SCPH) increased by over 18% during intraday trading. This is why it happened.
ScPharmaceuticals: The Third Time's A Charm
09:11am, Wednesday, 12'th May 2021
scPharmaceuticals received a second Complete Response Letter (CRL) on Furoscix rather than an FDA approval in December of 2020. The issues in the CRL are being addressed. The subcutaneous, home delive
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
08:00am, Wednesday, 12'th May 2021
FREEDOM clinical study on track for topline results in Q3 2021
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D.
08:00am, Wednesday, 17'th Feb 2021
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
08:00am, Thursday, 11'th Feb 2021
BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of scPharmaceuticals Inc. - SCPH
02:18am, Thursday, 10'th Dec 2020
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are
FDA Rejects scPharma's Heart Failure Drug For Second Time, Sending Biotech Stock Lower
10:33am, Monday, 07'th Dec 2020
Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-bas
scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference
08:00am, Thursday, 19'th Nov 2020
BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Monday, 16'th Nov 2020
Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration
scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
08:00am, Wednesday, 11'th Nov 2020
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
